UA117154C2 - Антагоністи s1p3 - Google Patents
Антагоністи s1p3Info
- Publication number
- UA117154C2 UA117154C2 UAA201607137A UAA201607137A UA117154C2 UA 117154 C2 UA117154 C2 UA 117154C2 UA A201607137 A UAA201607137 A UA A201607137A UA A201607137 A UAA201607137 A UA A201607137A UA 117154 C2 UA117154 C2 UA 117154C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antagonists
- formula
- alzheimer
- medicament
- disease
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195372.1A EP2878339A1 (en) | 2013-12-02 | 2013-12-02 | SIP3 antagonists |
| PCT/EP2014/075986 WO2015082357A1 (en) | 2013-12-02 | 2014-11-28 | S1p3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA117154C2 true UA117154C2 (uk) | 2018-06-25 |
Family
ID=49674243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201607137A UA117154C2 (uk) | 2013-12-02 | 2014-11-28 | Антагоністи s1p3 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9951017B2 (enExample) |
| EP (4) | EP2878339A1 (enExample) |
| JP (2) | JP6595475B2 (enExample) |
| KR (1) | KR102386815B1 (enExample) |
| CN (1) | CN106232182B (enExample) |
| AU (1) | AU2014359489B2 (enExample) |
| CA (1) | CA2932218C (enExample) |
| EA (1) | EA034218B1 (enExample) |
| NZ (1) | NZ721802A (enExample) |
| UA (1) | UA117154C2 (enExample) |
| WO (1) | WO2015082357A1 (enExample) |
| ZA (1) | ZA201604490B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| KR102131677B1 (ko) | 2018-03-20 | 2020-08-05 | 주식회사 아하 | 가이드 모듈 및 하폐수 처리용 산기장치 |
| BR112021004999A2 (pt) | 2018-09-17 | 2021-06-08 | Yungjin Pharm. Co., Ltd. | composto e método de inibição de cdk7 em um sujeito |
| KR102335637B1 (ko) * | 2020-03-13 | 2021-12-06 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
| CN116568671A (zh) * | 2020-10-16 | 2023-08-08 | 分子医学研究中心责任有限公司 | 杂环Cullin-RING泛素连接酶化合物及其用途 |
| WO2023275796A1 (en) * | 2021-07-01 | 2023-01-05 | Novartis Ag | Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors |
| JP2025526266A (ja) * | 2022-07-05 | 2025-08-13 | オーリジーン オンコロジー リミテッド | Ｃｄｋ１２／１３阻害剤としての置換ｎ－（ピリジン－２－イル）アセトアミド誘導体 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081756B1 (en) | 1981-12-14 | 1985-05-15 | MEDEA RESEARCH S.r.l. | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
| WO1998015278A1 (en) | 1996-10-07 | 1998-04-16 | Smithkline Beecham Corporation | Method for stimulating bone formation |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| CN1384832A (zh) | 1999-11-18 | 2002-12-11 | 诺瓦提斯公司 | 作为农药的氨基杂环基酰胺化合物 |
| ES2233660T3 (es) | 2000-05-03 | 2005-06-16 | F. Hoffmann-La Roche Ag | Activadores de glucokinasa alquinil fenil heteroaromaticos. |
| JP4742333B2 (ja) | 2000-11-13 | 2011-08-10 | 日本農薬株式会社 | Ｎ−チアジアゾリルシクロプロパンカルボン酸アミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| DK1341774T3 (da) | 2000-12-06 | 2006-06-12 | Hoffmann La Roche | Kondenserede heteroaromatiske glucokinase-aktivatorer |
| WO2003020313A1 (en) * | 2001-09-04 | 2003-03-13 | Ono Pharmaceutical Co., Ltd. | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| EP1458382A1 (en) * | 2001-12-21 | 2004-09-22 | Novo Nordisk A/S | Amide derivatives as gk activators |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| EA011297B1 (ru) | 2002-04-26 | 2009-02-27 | Ф. Хоффманн-Ля Рош Аг | Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| EP1594863A1 (en) * | 2003-02-11 | 2005-11-16 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| PL1700856T3 (pl) * | 2003-12-26 | 2016-05-31 | Kyowa Hakko Kirin Co Ltd | Pochodna tiazolu |
| WO2005075435A1 (en) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| JP2008521864A (ja) | 2004-12-03 | 2008-06-26 | トランステック・ファーマ、インコーポレイテッド | ヘテロ芳香族グルコキナーゼ活性化剤 |
| US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
| CA2621227A1 (en) | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| EP1935874A4 (en) * | 2005-10-12 | 2010-10-13 | Toa Eiyo Ltd | S1P3 RECEPTOR ANTAGONIST |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| NZ569327A (en) | 2005-12-28 | 2011-09-30 | Vertex Pharma | 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis |
| JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| WO2008119734A2 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | Process for the manufacture of organic compounds |
| WO2008141013A1 (en) * | 2007-05-08 | 2008-11-20 | Allergan, Inc. | S1p3 receptor inhibitors for treating pain |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| KR20100113518A (ko) | 2008-01-18 | 2010-10-21 | 아스텔라스세이야쿠 가부시키가이샤 | 페닐아세트아미드 유도체 |
| CA2716515A1 (en) * | 2008-02-21 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the cb2 receptor |
| PT2615085E (pt) | 2008-03-31 | 2015-10-09 | Vertex Pharma | Derivados piridilo como moduladores cftr |
| WO2009140624A2 (en) * | 2008-05-16 | 2009-11-19 | Takeda San Diego, Inc. | Glucokinase activators |
| EA201100311A1 (ru) | 2008-09-11 | 2011-10-31 | Пфайзер Инк. | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы |
| UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| US20120088800A1 (en) * | 2009-06-30 | 2012-04-12 | Allergan, Inc. | 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS |
| US8168795B2 (en) * | 2009-08-11 | 2012-05-01 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| WO2011133734A1 (en) * | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| WO2012082817A1 (en) * | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| US9658211B2 (en) * | 2012-04-18 | 2017-05-23 | Hemoshear, Llc | In vitro model for pathological or physiologic conditions |
| EP2878339A1 (en) * | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
-
2013
- 2013-12-02 EP EP13195372.1A patent/EP2878339A1/en not_active Withdrawn
-
2014
- 2014-11-28 EP EP19210115.2A patent/EP3689864A1/en not_active Withdrawn
- 2014-11-28 EA EA201691160A patent/EA034218B1/ru not_active IP Right Cessation
- 2014-11-28 CN CN201480074769.6A patent/CN106232182B/zh active Active
- 2014-11-28 JP JP2016536883A patent/JP6595475B2/ja active Active
- 2014-11-28 AU AU2014359489A patent/AU2014359489B2/en active Active
- 2014-11-28 CA CA2932218A patent/CA2932218C/en active Active
- 2014-11-28 US US15/100,326 patent/US9951017B2/en active Active
- 2014-11-28 EP EP14811790.6A patent/EP3086845B1/en active Active
- 2014-11-28 EP EP21155292.2A patent/EP3896068A1/en not_active Withdrawn
- 2014-11-28 UA UAA201607137A patent/UA117154C2/uk unknown
- 2014-11-28 NZ NZ721802A patent/NZ721802A/en unknown
- 2014-11-28 KR KR1020167017929A patent/KR102386815B1/ko active Active
- 2014-11-28 WO PCT/EP2014/075986 patent/WO2015082357A1/en not_active Ceased
-
2016
- 2016-07-01 ZA ZA201604490A patent/ZA201604490B/en unknown
-
2018
- 2018-03-16 US US15/923,837 patent/US20180201582A1/en not_active Abandoned
-
2019
- 2019-09-26 JP JP2019175781A patent/JP2020023512A/ja active Pending
-
2020
- 2020-01-24 US US16/751,472 patent/US11472772B2/en active Active
-
2022
- 2022-08-03 US US17/880,577 patent/US20220402875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA034218B1 (ru) | 2020-01-17 |
| EP3086845B1 (en) | 2019-11-20 |
| WO2015082357A1 (en) | 2015-06-11 |
| EP3896068A1 (en) | 2021-10-20 |
| US20220402875A1 (en) | 2022-12-22 |
| JP6595475B2 (ja) | 2019-10-23 |
| EP2878339A1 (en) | 2015-06-03 |
| US11472772B2 (en) | 2022-10-18 |
| HK1226017A1 (en) | 2017-09-22 |
| US9951017B2 (en) | 2018-04-24 |
| EP3689864A1 (en) | 2020-08-05 |
| CA2932218A1 (en) | 2015-06-11 |
| EP3086845A1 (en) | 2016-11-02 |
| CN106232182B (zh) | 2019-11-01 |
| US20200157052A1 (en) | 2020-05-21 |
| CA2932218C (en) | 2023-10-03 |
| JP2016539174A (ja) | 2016-12-15 |
| AU2014359489B2 (en) | 2020-01-30 |
| US20180201582A1 (en) | 2018-07-19 |
| US20160297762A1 (en) | 2016-10-13 |
| NZ721802A (en) | 2022-04-29 |
| AU2014359489A1 (en) | 2016-07-21 |
| KR20160093710A (ko) | 2016-08-08 |
| EA201691160A1 (ru) | 2016-11-30 |
| CN106232182A (zh) | 2016-12-14 |
| KR102386815B1 (ko) | 2022-04-14 |
| ZA201604490B (en) | 2019-11-27 |
| JP2020023512A (ja) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| EA201692280A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| IN2014DN03206A (enExample) | ||
| MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX351305B (es) | Antagonistas del receptor de mineralocorticoides. | |
| MY193728A (en) | Muscarinic receptor agonists | |
| MY169986A (en) | Benzimidazole-proline derivatives | |
| UA109661C2 (uk) | Фармацевтична композиція співкристалів трамадолу і коксибів | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| MY174648A (en) | Formulations of organic compounds | |
| MX2015011536A (es) | Nuevos antagonistas de receptores trpa1 de sulfamidas. | |
| PH12016500577A1 (en) | Piperazine derivatives and the use thereof as medicament | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. |